Unknown

Dataset Information

0

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.


ABSTRACT: Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph(+)) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph(+) leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.

SUBMITTER: Zabriskie MS 

PROVIDER: S-EPMC4160372 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie Matthew S MS   Eide Christopher A CA   Tantravahi Srinivas K SK   Vellore Nadeem A NA   Estrada Johanna J   Nicolini Franck E FE   Khoury Hanna J HJ   Larson Richard A RA   Konopleva Marina M   Cortes Jorge E JE   Kantarjian Hagop H   Jabbour Elias J EJ   Kornblau Steven M SM   Lipton Jeffrey H JH   Rea Delphine D   Stenke Leif L   Barbany Gisela G   Lange Thoralf T   Hernández-Boluda Juan-Carlos JC   Ossenkoppele Gert J GJ   Press Richard D RD   Chuah Charles C   Goldberg Stuart L SL   Wetzler Meir M   Mahon Francois-Xavier FX   Etienne Gabriel G   Baccarani Michele M   Soverini Simona S   Rosti Gianantonio G   Rousselot Philippe P   Friedman Ran R   Deininger Marie M   Reynolds Kimberly R KR   Heaton William L WL   Eiring Anna M AM   Pomicter Anthony D AD   Khorashad Jamshid S JS   Kelley Todd W TW   Baron Riccardo R   Druker Brian J BJ   Deininger Michael W MW   O'Hare Thomas T  

Cancer cell 20140814 3


Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph(+)) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosu  ...[more]

Similar Datasets

| S-EPMC8095092 | biostudies-literature
| S-EPMC6893878 | biostudies-literature
| S-EPMC3938434 | biostudies-literature
| S-EPMC6450432 | biostudies-literature
| S-EPMC6005845 | biostudies-literature
| S-EPMC6205183 | biostudies-literature
| S-EPMC8819354 | biostudies-literature
| S-EPMC3597744 | biostudies-literature
| S-EPMC3548169 | biostudies-literature